You are not logged in.

Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma

Subramanian, Nithya, Kanwar, Jagat R, Kanwar, Rupinder K. and Krishnakumar, Subramanian 2015, Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma, Nucleic acid therapeutics, vol. 25, no. 1, pp. 47-52, doi: 10.1089/nat.2014.0507.

Attached Files
Name Description MIMEType Size Downloads

Title Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma
Author(s) Subramanian, Nithya
Kanwar, Jagat R
Kanwar, Rupinder K.
Krishnakumar, Subramanian
Journal name Nucleic acid therapeutics
Volume number 25
Issue number 1
Start page 47
End page 52
Total pages 6
Publisher Mary Ann Liebert
Place of publication New Rochelle, N. Y.
Publication date 2015-02
ISSN 2159-3345
Keyword(s) Apoptosis
Aptamers, Nucleotide
Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
Genetic Therapy
Humans
MicoRNAs
RNA Interference
Retinoblastoma
Summary The miR-17∼92. or oncomiR-1, cluster encodes oncogenic microRNAs (miRNAs), and it also promotes retinoblastoma (RB) tumor formation. Antagomir and miRNA mimics based approaches are widely tried against oncogenic and tumor suppressive miRNAs. Other methods for targeting cancer related miRNAs are still under development. In the current study, we focused on the pri-miRNA-17∼92 aptamer (pri-apt), which can potentially replace the mix of five antagomirs by one aptamer that function to abrogate the maturation of miR-17, miR-18a, and miR-19b (P<0.05) for targeting RB. We used RB cell lines WERI-Rb1 and Y79 as an in vitro model. Cellular changes upon transfecting the pri-apt led to S-phase arrest in WERI-Rb1 cells and onset of apoptosis in both Y79 and WERI-Rb1 cell lines. There was increased cytotoxicity as measured by lactate dehydrogenase activity in pri-apt treated Y79 cells (P<0.05), and significant inhibition of cell proliferation was observed in both of the cell lines. Thus we showed the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.
Language eng
DOI 10.1089/nat.2014.0507
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Mary Ann Liebert
Persistent URL http://hdl.handle.net/10536/DRO/DU:30075685

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 4 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 76 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Tue, 20 Oct 2015, 09:26:10 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.